Posts Tagged ‘biotech’

Now that December is here, I thought it would be neat to look back at what our readers found most interesting last month. Below are the top five blog posts Perficient’s life sciences practice wrote in November – they’re ranked in order of popularity, with number one being the most viewed piece. Top 25 Biotech Companies European […]

Pharmaceutical companies selling their products in the UK need to consider the impact Brexit will have on their operations. Some changes will need to be made before the UK leaves the European Union on March 30, 2019. In a press release, the European Medicines Agency (EMA) said: “The guidance document outlines the practical and simplified […]

We’re all intrigued by rankings and flock to them for good reason. When it comes to ranking companies by market capitalization, you can assume that the named companies are leaders in their own right. They never stop innovating. They never stop changing. They never stop investing in their business. These are companies that we can […]

I recall hearing Michael Farrell, the CEO of ResMed, speak about how important the Internet of Things (IoT) is to his company. There’s probably not a better case study of IoT in life sciences than ResMed. The medical device company specializes in sleep apnea products and solutions. They also happen to be the makers of […]

Now that October is here, I thought it would be neat to look back at what our readers found most interesting last month. Below are the top five blog posts Perficient’s life sciences practice wrote in September – they’re ranked in order of popularity, with number one being the most viewed piece. How Merck & Facebook Are […]

Mark Zuckerberg, Facebook’s CEO, recently took a trip to Alaska as part of his personal challenge to have visited every state in the U.S. by the end of 2017. In a post, he shared his thoughts on Alaska’s Permanent Fund Dividend, which provides residents with a portion of the oil revenue the state makes. Each […]

When I’m approached by clients to discuss safety projects, it is generally about implementing Oracle’s Argus Safety, upgrading the system, or discussing their ability to comply with regulatory requirements. Recently, I was asked about migrating from a legacy drug safety database to Argus. We discussed the methods available, such as leveraging an Oracle dump, a […]

E2B(R3) So, there we have it, the European Medicines Agency (EMA) has finally issued a statement, which confirms the date of release for the bigger, better EudraVigilance: November 22, 2017. Time to go into panic mode? Absolutely not. But, here are some of the things you should be thinking about as the deadline approaches: Training […]

Just last week, the house voted to repeal Obamacare, and much has already been covered in articles readily available on the internet. But the Senate has already stated they will write up new legislation that will take into consideration the House bill. No timeline for the Senate to produce its new legislation has been set, […]

In a time in which research and development costs are at an all-time high, The Wall Street Journal just shared how pharmaceutical companies are starting to look for outside help to fund trials: everything from phase II all the way through the commercial phase. Partnering with private equity firms, such as NovaQuest and Avillion, is […]

Happy May Day! Now that May is here, I thought it would be neat to look back at what our readers found most interesting last month. Below are the top five blog posts Perficient’s life sciences practice wrote in April – they’re ranked in order of popularity, with number one being the most viewed piece. My Colleagues […]

When discussing the impact the United States’ new administration may have on pharmaceutical companies, GlaxoSmithKline’s Andrew Witty may have said it best: “I’ve had 30 years in this industry, and there’s never been a dull year. And there’s never been a year where it hasn’t felt challenging and interesting. And I suspect the next 30 years won’t be […]